Opthea Ltd-spon Adr (OPT)

$2.12

+0.05

(+2.42%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $2.10
    $2.14
    $2.12
    downward going graph

    0.94%

    Downside

    Day's Volatility :1.87%

    Upside

    0.93%

    downward going graph
  • $1.60
    $4.40
    $2.12
    downward going graph

    24.53%

    Downside

    52 Weeks Volatility :63.64%

    Upside

    51.82%

    downward going graph

Returns

PeriodOpthea Ltd-spon AdrSector (Health Care)Index (Russel 2000)
3 Months
-37.28%
6.4%
0.0%
6 Months
-24.01%
6.0%
0.0%
1 Year
-33.09%
8.5%
0.0%
3 Years
-71.04%
14.6%
-20.8%

Highlights

Market Capitalization
192.5M
Book Value
- $0.07
Earnings Per Share (EPS)
-2.22
Wall Street Target Price
12.76
Profit Margin
0.0%
Operating Margin TTM
-46350.64%
Return On Assets TTM
-64.33%
Return On Equity TTM
-3383.08%
Revenue TTM
390.4K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
2.6%
Gross Profit TTM
218.4K
EBITDA
-164.9M
Diluted Eps TTM
-2.22
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-12.37
EPS Estimate Next Year
-10.83
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    11%Buy
    33%Hold
    55%Sell
Based on 9 Wall street analysts offering stock ratings for Opthea Ltd-spon Adr(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
2
Hold
3
2
2
Sell
5
6
6

Analyst Forecast

What analysts predicted

Upside of 501.89%

Current $2.12
Target $12.76

Company Financials

FY19Y/Y Change
Revenue
79.0K
-
Net Income
-10.5M
↑ 20.44%
Net Profit Margin
-13.3K%
-
FY20Y/Y Change
Revenue
40.8K
↓ 47.5%
Net Income
-7.6M
↓ 25.9%
Net Profit Margin
-18.8K%
↓ 5468.89%
FY21Y/Y Change
Revenue
51.4K
↑ 16.17%
Net Income
-34.0M
↑ 309.22%
Net Profit Margin
-66.1K%
↓ 47325.73%
FY22Y/Y Change
Revenue
62.4K
↑ 32.17%
Net Income
-63.9M
↑ 104.69%
Net Profit Margin
-102.4K%
↓ 36266.34%
FY23Y/Y Change
Revenue
72.3K
↑ 19.54%
Net Income
-95.0M
↑ 53.55%
Net Profit Margin
-131.5K%
↓ 29116.08%
Q2 FY22Q/Q Change
Revenue
31.4K
↑ 49.67%
Net Income
-37.9M
↑ 49.67%
Net Profit Margin
-120.8K%
↑ 0.09%
Q3 FY22Q/Q Change
Revenue
154.1K
↑ 237.59%
Net Income
-60.3M
↑ 9.38%
Net Profit Margin
-39.1K%
↑ 81627.49%
Q4 FY22Q/Q Change
Revenue
52.0K
↓ 66.22%
Net Income
-77.0M
↑ 27.75%
Net Profit Margin
-148.0K%
↓ 108840.77%
Q1 FY23Q/Q Change
Revenue
140.8K
↑ 170.49%
Net Income
-48.9M
↓ 36.45%
Net Profit Margin
-34.8K%
↑ 113203.35%
Q2 FY23Q/Q Change
Revenue
55.9K
↓ 60.31%
Net Income
-64.9M
↑ 32.69%
Net Profit Margin
-116.2K%
↓ 81445.13%
Q4 FY23Q/Q Change
Revenue
61.3K
↑ 9.67%
Net Income
-96.9M
↑ 49.31%
Net Profit Margin
-158.2K%
↓ 41999.42%
FY18Y/Y Change
Total Assets
33.8M
↓ 22.1%
Total Liabilities
5.8M
↑ 268.06%
FY19Y/Y Change
Total Assets
13.0M
↓ 45.38%
Total Liabilities
2.3M
↓ 44.7%
FY20Y/Y Change
Total Assets
23.6M
↑ 85.3%
Total Liabilities
2.3M
↑ 5.06%
FY21Y/Y Change
Total Assets
103.8M
↑ 304.06%
Total Liabilities
2.3M
↓ 7.4%
FY22Y/Y Change
Total Assets
41.3M
↓ 56.62%
Total Liabilities
8.3M
↑ 286.43%
FY23Y/Y Change
Total Assets
65.8M
↑ 64.27%
Total Liabilities
69.7M
↑ 765.76%
Q2 FY22Q/Q Change
Total Assets
41.3M
↓ 25.17%
Total Liabilities
8.3M
↓ 25.17%
Q3 FY22Q/Q Change
Total Assets
240.8M
↑ 301.01%
Total Liabilities
152.5M
↑ 1163.54%
Q4 FY22Q/Q Change
Total Assets
105.0M
↓ 36.04%
Total Liabilities
66.5M
↓ 36.04%
Q1 FY23Q/Q Change
Total Assets
147.5M
↓ 4.2%
Total Liabilities
156.3M
↑ 60.24%
Q2 FY23Q/Q Change
Total Assets
65.8M
↓ 33.15%
Total Liabilities
69.7M
↓ 33.15%
Q4 FY23Q/Q Change
Total Assets
166.5M
↑ 68.79%
Total Liabilities
213.4M
↑ 104.24%
FY18Y/Y Change
Operating Cash Flow
-19.9M
↑ 229.79%
Investing Cash Flow
-34.4K
↓ 120.42%
Financing Cash Flow
403.8K
↓ 98.79%
FY19Y/Y Change
Operating Cash Flow
-8.4M
↓ 40.25%
Investing Cash Flow
225.4K
↓ 1032.61%
Financing Cash Flow
4.3M
↑ 1431.36%
FY20Y/Y Change
Operating Cash Flow
-3.9M
↓ 52.24%
Investing Cash Flow
328.3K
↑ 48.22%
Financing Cash Flow
23.2M
↑ 444.31%
FY21Y/Y Change
Operating Cash Flow
-34.2M
↑ 700.51%
Investing Cash Flow
492.2K
↑ 37.99%
Financing Cash Flow
87.7M
↑ 247.45%
FY22Y/Y Change
Operating Cash Flow
-49.1M
↑ 56.62%
Investing Cash Flow
-11.6K
↓ 102.58%
Financing Cash Flow
118.1K
↓ 99.85%
FY23Y/Y Change
Operating Cash Flow
-80.4M
↑ 69.07%
Investing Cash Flow
-14.6K
↑ 29.83%
Financing Cash Flow
111.5M
↑ 97387.2%
Q2 FY22Q/Q Change
Operating Cash Flow
-42.4M
↑ 116.78%
Investing Cash Flow
-5.2K
↑ 0.0%
Financing Cash Flow
-39.7K
↑ 116.78%
Q3 FY22Q/Q Change
Operating Cash Flow
-54.2M
↓ 12.18%
Investing Cash Flow
-3.5K
↓ 53.99%
Financing Cash Flow
130.7M
↓ 226477.28%
Q4 FY22Q/Q Change
Operating Cash Flow
-69.2M
↑ 27.75%
Investing Cash Flow
-3.5K
↑ 0.0%
Financing Cash Flow
167.0M
↑ 27.75%
Q1 FY23Q/Q Change
Operating Cash Flow
-38.4M
↓ 44.53%
Investing Cash Flow
-7.5K
↑ 112.74%
Financing Cash Flow
67.3K
↓ 99.96%
Q2 FY23Q/Q Change
Operating Cash Flow
-50.5M
↑ 31.55%
Investing Cash Flow
-7.5K
↑ 0.0%
Financing Cash Flow
-965.9K
↓ 1534.29%

Technicals Summary

Sell

Neutral

Buy

Opthea Ltd-spon Adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Opthea Ltd-spon Adr
Opthea Ltd-spon Adr
6.0%
-24.01%
-33.09%
-71.04%
-82.76%
Moderna, Inc.
Moderna, Inc.
-9.19%
21.5%
-4.18%
-62.27%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.99%
12.81%
44.78%
82.21%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-7.34%
24.69%
58.81%
196.23%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.88%
11.69%
35.62%
150.46%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Opthea Ltd-spon Adr
Opthea Ltd-spon Adr
NA
NA
NA
-12.37
-33.83
-0.64
NA
-0.07
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Opthea Ltd-spon Adr
Opthea Ltd-spon Adr
Sell
$192.5M
-82.76%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Opthea Ltd-spon Adr

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 55.86K → 61.27K (in $), with an average increase of 8.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -48.92M → -96.93M (in $), with an average decrease of 41.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.8% return, outperforming this stock by 91.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 196.2% return, outperforming this stock by 267.2%

Institutional Holdings

  • VGI PARTNERS PTY Ltd

    3.51%
  • Baker Bros Advisors LP

    2.63%
  • Victory Capital Management Inc.

    1.03%
  • Teacher Retirement System Of Texas

    0.75%
  • Millennium Management LLC

    0.09%
  • BMO Capital Markets Corp.

    0.06%

Company Information

opthea limited (formerly circadian technologies) is a public australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. opthea's lead compound, opt-302, blocks two members of the vascular endothelial growth factor family, namely vegf-c and vegf-d, which cause blood vessels to grow and leak. aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet amd). opthea is currently investigating opt-302 in an ongoing phase 1/2a clinical trial in wet amd patients. enquiries can be directed to: info@opthea.com

Organization
Opthea Ltd-spon Adr
Employees
24
CEO
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.
Industry
Health Technology

FAQs